Vanguard Information Technology ETF (VGT)
| Assets | $89.31B |
| Expense Ratio | 0.09% |
| PE Ratio | 38.00 |
| Shares Out | 138.82M |
| Dividend (ttm) | $3.72 |
| Dividend Yield | 0.60% |
| Ex-Dividend Date | Dec 18, 2024 |
| Payout Ratio | 22.19% |
| 1-Year Return | +24.25% |
| Volume | 597,244 |
| Open | 642.78 |
| Previous Close | 641.51 |
| Day's Range | 623.92 - 642.78 |
| 52-Week Low | 478.25 |
| 52-Week High | 648.76 |
| Beta | 1.16 |
| Holdings | 319 |
| Inception Date | Jan 26, 2004 |
About VGT
Fund Home PageThe Vanguard Information Technology ETF (VGT) is an exchange-traded fund that mostly invests in information technology equity. The fund tracks a market cap-weighted index of companies in the US information technology sector. VGT was launched on Jan 26, 2004 and is issued by Vanguard.
Top 10 Holdings
57.72% of assets| Name | Symbol | Weight |
|---|---|---|
| Apple Inc. | AAPL | 16.85% |
| NVIDIA Corporation | NVDA | 13.90% |
| Microsoft Corporation | MSFT | 13.35% |
| Broadcom Inc. | AVGO | 4.23% |
| Salesforce, Inc. | CRM | 1.97% |
| Oracle Corporation | ORCL | 1.71% |
| Cisco Systems, Inc. | CSCO | 1.48% |
| Accenture plc | ACN | 1.48% |
| International Business Machines Corporation | IBM | 1.45% |
| ServiceNow, Inc. | NOW | 1.29% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 18, 2024 | $0.7766 | Dec 20, 2024 |
| Sep 27, 2024 | $0.9171 | Oct 1, 2024 |
| Jun 28, 2024 | $0.7624 | Jul 2, 2024 |
| Mar 22, 2024 | $1.259 | Mar 27, 2024 |
| Dec 19, 2023 | $0.7946 | Dec 22, 2023 |
| Sep 28, 2023 | $0.8814 | Oct 3, 2023 |
News
ETF Flowdown: Off to the Races in 2025
One month into 2025, and ETFs are already off to the races, hauling in over $100 billion in net inflows in January. Hefty gains across the board reflect continued bullish sentiment on the stock market...
ETF Prime: Chang Highlights ETF Flow Trends in 2025
On this week's episode of ETF Prime, Kirsten Chang, senior industry analyst at VettaFi, joined Nate Geraci to discuss ETF flow trends in 2025. Afterward, Stone Ridge's Nate Conrad shared details on th...
AI-themed ETFs plunge in wake of DeepSeek news
Prices of exchange-traded funds with outsize exposure to Nvidia plunged in the initial hours of trading on Monday in reaction to news that a Chinese startup has launched a powerful new artificial inte...
XSW Seems Better Than VGT In The Age Of DOGE
The SPDR S&P Software & Services ETF outperformed the Vanguard Information Technology Index Fund ETF due to anticipated growth in mid- and small-cap tech companies benefiting from deregulation. XSW's ...
VGT: The Only One To Hold
The technology sector, despite slowing earnings growth, remains attractive due to solid future earnings expectations and AI potential, with Vanguard Information Technology Index Fund ETF Shares (VGT) ...
Vergent Bioscience Receives FDA Fast Track Designation for Abenacianine for Injection (VGT-309) to Help Surgeons Visualize Tumors in the Lung During Surgery
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that the U.S. Food & Drug Administration (FDA) has granted ...
VGT: Promising Long-Term Outlook With Short-Term Uncertainty
The tech sector thrived in 2024, with standout performances from Apple, Microsoft, and Nvidia, but potential volatility looms ahead. VGT is highly concentrated in its top three holdings, which poses r...
VGT: Why It Is A Strong Large Growth ETF
VGT has outperformed other large-cap ETFs like SPY and QQQ, making it a top recommendation for long-term holding due to its technology focus. Technology is the key growth driver, with ETFs like VGT ma...
VGT: Tech Stocks Look Tired
Mega-cap tech stocks have led the market, but VGT's heavy concentration in Apple, Microsoft, and NVIDIA poses risks if their charts turn bearish. VGT is not a diversified fund; nearly 60% of its holdi...
Vergent Bioscience Completes Enrollment in Phase 2 VISUALIZE Trial Evaluating Potential of Abenacianine for Injection (VGT-309) to Improve Tumor Visualization During Cancer Surgery
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced completion of patient enrollment in the company's Phase 2, ...
VGT: Less Attractive In An Era Of Mega Caps
VGT's concentrated portfolio, with Apple, Nvidia, and Microsoft at 45%, reduces diversification and limits upside potential to 6%. VGT tracks the MSCI US IMI/Information Technology 25/50 Index, which ...
VGT: A Fund For Technology's Next Big Run
VGT is a solid technology sector fund with a low expense ratio and superior risk-adjusted performance, despite slightly lagging its peers in total return. Technology's recent underperformance is due t...
VGT Is A Stronger Investment Option Than QQQ
VGT offers a competitive investment strategy with a lower expense ratio (10bps) and higher yield (0.65%) compared to QQQ, making it a strong buy for tech sector exposure. VGT's portfolio is highly con...
VGT: Relative Strength Suggests Caution Warranted
The Vanguard Information Technology ETF (VGT) is dominated by Apple, NVIDIA, and Microsoft, which together account for 44% of the ETF. The VGT ETF's recent underperformance relative to the S&P 500 sug...
VGT: Insane Concentration Risk
Tech is currently the most overcrowded sector, likely facing a meaningful correction soon, making it a risky allocation right now. Vanguard Information Technology ETF offers broad tech exposure but ha...
VOO, VGT, DIA ETF stocks suffered a harsh reversal: I'm buying
American stocks dived on Friday as concerns that the US was moving into a hard landing continued. The Vanguard S&P 500 ETF (VOO) ETF slumped to $490 on Friday, down by over 5.69% from its highest leve...
VGT: Sector-Specific Concentration And Long-Term Exposure
Exchange-Traded Funds can provide significant portfolio diversification, investing with long-term strategies. VGT is a top-heavy fund with holdings weighted in the Information Technology sector. The f...
VGT: A Higher-Risk Fund That Looks Overvalued Right Now
Vanguard Information Technology ETF has outperformed since 2004, but is heavily concentrated in a few large-cap tech companies. VGT has consistently underperformed the broader NASDAQ index, with core ...
Vergent Bioscience Data Published in The Annals of Thoracic Surgery Demonstrate VGT-309 May Help Surgeons Visualize Tumor Tissue in the Lung During Surgery
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that data published in The Annals of Thoracic Surgery reinf...
VGT: Buy This Basket With An Impressive Assortment Of Eggs
The current US economic landscape is unique. Many varying economic forces, making an ideal soft landing a matter of when. VGT has a unique portfolio concentrated enough to reap long-term benefits of t...
VGT: Last Year, IYW Was The Better Choice, But Now, SCHG Offers Safer Tech Exposure
Last Year, I predicted IYW would be a better investment than VGT. IYW has outperformed due to its greater concentration in fewer stocks, and it's tracking an index that includes stocks VGT's index exp...
VGT: Continued Strength As The AI Base Broadens
Vanguard Information Technology ETF offers low fees, and a dividend yield, gaining over 35% since September last year. VGT's outperformance is due to the innovation factor, with companies like Nvidia ...